Drug Topics
JUNE 12, 2025
SF 383 prohibits PBMs from limiting patient choice of pharmacy, unfairly excluding pharmacies from networks, and forces them to reimburse pharmacies no less than what they pay affiliated pharmacies for the same drug.
PhRMA
JUNE 12, 2025
As lawmakers in Lansing debate health care legislation, new evidence reveals a staggering—and deeply troubling—reality: big, tax-exempt hospitals in the state are marking up the price of prescription medicines by nearly $10 billion a year. The federal 340B program is running unchecked with limited transparency and accountability, and comprehensive federal reform is needed to stop abuse of the program.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 12, 2025
Direct-to-consumer drug sales may undermine patient care and threaten independent pharmacies by reducing access to personalized, comprehensive medication management.
STAT
JUNE 12, 2025
When House Republicans voted in the wee hours of the morning of May 22 to cut approximately $700 billion from Medicaid , they moved one step closer to rendering dangerously vulnerable the millions of Medicaid recipients struggling with mental illness and substance use disorder. Medicaid, which covers more than 72 million Americans, is the single largest payer of behavioral health services , which includes mental health and substance use disorder treatment.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JUNE 12, 2025
This novel mechanism of action provides an alternative therapy for patients with recurrence or those who may not tolerate current first-line therapies.
Pharmacy Times
JUNE 12, 2025
Innovative strategies are essential to recruit pharmacy students and transform practices, ensuring equitable access to pharmacy services in underserved areas.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JUNE 12, 2025
Patients with chronic kidney disease (CKD) and type 2 diabetes receiving both treatments had greater reductions in urinary albumin-to-creatinine ratio.
Drug Topics
JUNE 12, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Pharmacy Times
JUNE 12, 2025
Amy Duong, PharmD, BCACP, highlights pharmacists' essential responsibilities in chronic inflammatory demyelinating polyneuropathy (CIDP) patient care and immunoglobulin therapy management.
Drug Topics
JUNE 12, 2025
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JUNE 12, 2025
Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.
PharmaVoice
JUNE 12, 2025
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
pharmaphorum
JUNE 12, 2025
MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.
DiversifyRx
JUNE 12, 2025
Hiring pharmacists or technicians shouldn’t feel like pulling teeth, but for many independent pharmacy owners, it does. You post your job opening, wait for the flood of qualified candidates, and instead…crickets. Here’s the hard truth: If you’re struggling to attract applicants, the problem might not be the talent pool; it could be your approach.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JUNE 12, 2025
Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Oncology -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -W
STAT
JUNE 12, 2025
As an adoptee who was placed in foster care at 18 months old, I’ve never known my full racial heritage, family tree, or medical history. People have often suggested I try 23andMe or a similar company to get more information on my genetics. But I’ve always felt uneasy about it. So, I felt a little vindicated when I saw the news that Regeneron Pharmaceuticals is set to acquire 23andMe , including its troves of customer data, for $256 million.
Pharmafile
JUNE 12, 2025
Ascend Advanced Therapies, a contract development and manufacturing organisation based in Maryland, US, has received good manufacturing practice (GMP) certification for quality control (QC) testing at its site in Munich, Germany. This will streamline testing and release of adeno-associated (AAV)-based gene therapy. The Munich facility is now permitted to perform advanced commercial assays for DNA […] The post Ascend granted certification for quality control testing at Munich facility appea
European Pharmaceutical Review
JUNE 12, 2025
Researchers have developed a once-weekly oral capsule with an innovative delayed drug release mechanism. This development could help certain patients, such as those with schizophrenia , to take their medicines more consistently. As the drug device can be delivered orally , the new pill “represents an important option that can assist with adherence for the many patients who would prefer oral medications versus injectable formulations,” explained Leslie Citrome, a Clinical Professor of psychiatry
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JUNE 12, 2025
New research reveals how individual blood sugar responses to carbohydrates vary, highlighting the importance of personalized dietary approaches for diabetes management.
pharmaphorum
JUNE 12, 2025
Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
Hospital Pharmacy Europe
JUNE 12, 2025
The recruitment and retention of clinical and non-clinical staff is a persistent challenge across secondary care services. Noting a concerning vacancy rate, the pharmacy department at East Kent Hospitals University NHS Foundation Trust set about determining the reasons for this and identifying solutions. Pharmacists Alice Lo and Rebecca Morgan discuss the findings of their flexible working survey and the strategies they’ve implemented to maintain a positive working environment and better support
European Pharmaceutical Review
JUNE 12, 2025
Regulatory bodies like the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are emphasising the importance of data quality for AI applications in healthcare. High-quality and well-structured data and metadata are characterised by accuracy, consistency and completeness, which is essential for reliable insights and trustworthy AI outputs.
Hospital Pharmacy Europe
JUNE 12, 2025
The Royal Pharmaceutical Society is calling on the Government to commit to upgrading digital systems in hospital pharmacy as the chancellor Rachel Reeves announces her much-anticipated spending review. The NHS will receive a £29bn real terms funding boost over the next three years, Ms Reeves said. This equates to a 3% increase in annual day-to-day spending from 2023/24 to 2028/29, making the spending £226bn by the end of the period.
Pharmaceutical Technology
JUNE 12, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
STAT
JUNE 12, 2025
Taxpayers will send an estimated $86 billion to Medicare Advantage insurers this year to pay for supplemental benefits for their members, or 17% of total payments to those plans. But how that money is spent, and how much members actually use those benefits, remains a black hole, according to a new report from a group of Medicare experts. Medicare pays MA plans in the form of what’s known as rebates to help fund supplemental benefits, and that funding has shot up by more than 300% over the
PharmaShots
JUNE 12, 2025
Shots: Novartis has reported P-IIIb ( APPULSE-PNH ) trial data assessing Fabhalta (iptacopan; 200mg, BID, PO) for 24wks. in 52 PNH adults with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab) Trial showed a 2.01 g/dL mean Hb increase, with 92.7% pts achieving ≥12g/dL & no transfusions over 24wks. It also depicted improved fatigue per FACIT-Fatigue score (+4.88 at Day 84 & +4.29 at Day 168), along with sustained intravascular hemolysis control & resolv
STAT
JUNE 12, 2025
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they contract respiratory syncytial virus. Previously the vaccine, sold under the name mResvia, was only licensed for use in adults aged 60 and older.
Pharmafile
JUNE 12, 2025
Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders. These are ultra-rare diseases, including alpha-mannosidosis and Krabbe disease, that affect the central nervous system and have limited treatment options.
STAT
JUNE 12, 2025
If Health and Human Services Secretary Robert F. Kennedy Jr. wants to “clean up the corruption and conflicts” at HHS, he is going about it the wrong way. I study conflicts of interest at federal agencies. While industry influence is a widely shared concern, Kennedy’s dismissal of all the members of the Centers for Disease Control and Prevention vaccine advisory committee, and the rapid hiring of eight replacements , could easily misfire.
Viseven
JUNE 12, 2025
Speed and quality are no longer the only benchmarks for pharma and life sciences content creation. In pharma and life sciences, where compliance is a non-negotiable rule and tools often don’t play well together, marketers need more than just AI — they need a solution that connects the dots and respects the rules. That’s exactly the thinking that led us to conceptualize, create, and now release eVa — a new AI agent within the eWizard Content Experience Platform.
STAT
JUNE 12, 2025
Systematic reviews, which involve pooling data from multiple studies and analyzing them together, are increasingly popular as a way to produce more authoritative conclusions than can be derived from the individual smaller papers. In recent weeks, systematic reviews have been used to justify policy around gender affirming care as well as in the MAHA report.
PharmaShots
JUNE 12, 2025
Shots: The US FDA has approved mRESVIA (mRNA-1345) to prevent lower respiratory tract disease caused by RSV in individuals (18-59yrs.) at risk; expected to be available in US for the 2025–2026 respiratory virus season Approval was based on P-III trial assessing safety & immunogenicity of mRESVIA in adults (18-59yrs.) at increased risk for RSV-associated lower respiratory tract disease Trial met prespecified non-inferiority immunobridging criteria compared to adults (≥60yrs.) in P-III study ,
Pharmaceutical Technology
JUNE 12, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
Expert insights. Personalized for you.
545 
Let's personalize your content